Home›Research›Compare›CJC-1295 (without DAC) vs Hexarelin
Peptide ComparisonCJC-1295 (without DAC) vs Hexarelin
Both are GH / IGF Axis peptides.
CJC-1295 (without DAC)
CJC 1295
Half-life: ~30 minutes
454 providers listed
Hexarelin
Examorelin
Half-life: ~30-60 minutes
23 providers listed
CJC-1295 (without DAC) is carried by more providers on PeptideBase (454 vs 23); otherwise the two are closely matched on the measures we track.
CJC-1295 (without DAC)
Half-life
~30 minutes
Hexarelin
Half-life
~30-60 minutes
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | CJC-1295 (without DAC) |
| More provider options (454 vs 23) | CJC-1295 (without DAC) |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
CJC-1295 (without DAC)
Hexarelin
CJC-1295 (without DAC)
Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)…
Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune syst…
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Imp…
About CJC-1295 (without DAC)
CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH analog that binds and activates pituitary GHRH receptors to stimulate brief, pulsatile growth hormone release. Lacking the Drug Affinity Complex, it is not albumin-bound and clears within roughly half an hour, producing discrete GH pulses rather than the sustained elevation of the DAC form.
About Hexarelin
Potent synthetic GHRP; strongest GH secretagogue in its class; also activates CD36 scavenger receptor for cardioprotective effects
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
CJC-1295 (without DAC)
Class-based (investigational)
Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.
global — WADA
This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.
sourceHexarelin
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
CJC-1295 (without DAC)
Ipamorelin
Research suggests Ipamorelin and CJC-1295 may produce enhanced growth hormone release effects when combined. CJC-1295 provides sustained GHRH receptor stimulation while Ipamorelin provides pulsatile ghrelin receptor stimulation — complementary pathways studied in GH secretion research.
GLP-1 agonists
Research notes metabolic pathway overlap between growth hormone-releasing peptides and GLP-1 agonists. Both compound classes influence metabolic signaling; limited research has studied their combined effects. Consult your prescriber before combining.
CJC-1295 (without DAC)
Hexarelin
Where to source these peptides
CJC-1295 (without DAC)
454 listed
Browse directory →
Providers offeringHexarelin
23 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More GH / IGF Axis Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). CJC-1295 (without DAC) vs Hexarelin — Per-mg Price Comparison. Retrieved August 26, 2026, from https://peptidebase.io/peptides/compare/cjc-1295/hexarelin